1% BSA was added for 2 h at 37°C. Subsequently, plates were washed, and 100 μL Talazoparib purchase streptavidin-AP diluted 1:225 in PBS/0.1% BSA (DAKO) was added for 1 h at 37°C. After washing, the assay was developed for 8–15 min until the spots were clearly visible using BCIP/NBT alkaline phosphatase substrate (Sigma). The reaction was stopped by rinsing with distilled water.

The membranes were air dried overnight before the spots were counted with an ELISPOT reader. The cut-off was mean OD+ 2SD of the medium background counts, i.e. less than six spots was taken as background. Freshly isolated human PBMC (4×105 cells) were cultured for 5 days in triplicate in the presence of antigen, hnRNP-A2 peptides 117–133 or 120–133 (10 μM),

or PHA (1/50), with or without 5 μg/mL anti-HLA class II Ab (Tu39/ Cat 555556, BD-PharMingen) in a final volume of 200 μL complete RPMI medium, as for the ELISPOT assay. Control wells contained PBMC with medium alone. During the last 16–18 h of culture, 0.5 μCi/well tritiated thymidine (Amersham Biosciences, Freiburg, Germany) was added, and the incorporated radioactivity was measured by scintillation counting and expressed as cpm. Results are given as stimulation index (SI) defined by the ratio of (mean cpm obtained in cultures with antigen with or without Ab): (mean cpm obtained Selleckchem Venetoclax in cultures with medium only). An SI ≥2 was regarded as positive response 8. Anti-hnRNP-A2 (RA33) Ab were detected by ELISA (IMTEC, Berlin, Germany) and by Western immunoblotting, using recombinant antigens, as previously described 10. B-cell epitope mapping in mouse sera was performed by standard ELISA using MaxiSorp (Nunc) plates coated with 10 μM of each 280 peptides spanning the hnRNP-A2 protein and blocked with PBS 2% BSA. B-cell epitopes in human sera were identified as follows: peptides (10 μM) or TT (100 ng/mL) were covalently bound to Peptide Immobilizer plates (Nunc) in 0.1 M carbonate buffer, pH 9.6, overnight at 4°C. Afterwards and in all the following

steps, plates were washed with PBS 0.1% Tween-20. Sera from patients and controls were diluted 1/200 in PBS 0.1% Tween-20 and incubated 1 h Histidine ammonia-lyase at 37°C. Then, biotin-labeled anti-human IgG (1/2000 from Southern Biotech.) followed by streptavidin-HRPO (1/5000), both diluted in PBS 0.1% Tween-20, were used. Results are presented as mean OD for each sample tested in duplicate. When indicated, differences between groups were evaluated using a two-tailed Mann–Whitney or Fisher test. Differences were considered to be statistically significant at p<0.05. This work was supported by CeMM, Center for Molecular Medicine of the Austrian Academy of Sciences (M. H., B. M.), by funding from the European Community’s Sixth Framework Programme FP6 under grant agreement number LSHB-CT-2006-018661 (S.T.), and the Seventh Framework Programme FP7 under grant agreement number HEALTH-F2-2008-223404 (B. M.).